New treatments for cancer, diabetes, and heart disease — you may have a pig to thank

PUBLIC RELEASE DATE:

24-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 24, 2014--Genetically engineered pigs, minipigs, and microminipigs are valuable tools for biomedical research, as their lifespan, anatomy, physiology, genetic make-up, and disease mechanisms are more similar to humans than the rodent models typically used in drug discovery research. A Comprehensive Review article entitled "Current Progress of Genetically Engineered Pig Models for Biomedical Research," describing advances in techniques to create and use pig models and their impact on the development of novel drugs and cell and gene therapies, is published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website at http://online.liebertpub.com/doi/full/10.1089/biores.2014.0039.

Gkhan Gn and Wilfried Kues, Friedrich-Loeffler-Institute (Neustadt, Germany), Istanbul Technical University, and Istanbul University Faculty of Veterinary Medicine (Turkey), discuss the technologies that have made it possible to develop transgenic pig models of human diseases, such as targeted gene transfer and genome sequencing. The authors review current progress in creating transgenic pig models for cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, ophthalmology, and xenotransplantation. These models will enable researchers to study disease processes, identify new drug targets, test novel cell therapies to restore diseased tissues and organs, and assess methods to correct or replace mutated genes.

"This review provides an excellent update of recent progress in the field of pig transgenics for biomedical research," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website at http://www.liebertpub.com/biores.

About the Publisher

View post:
New treatments for cancer, diabetes, and heart disease -- you may have a pig to thank